QIAGEN Expands Integrated Coronavirus NGS and Software Solutions to Accelerate COVID-19 Research

Author's Avatar
Aug 19, 2020
Article's Main Image

QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) launched the innovative QIAseq SARS-CoV-2 Primer Panel for next-generation sequencing (NGS) of the novel coronavirus genome, along with integrated analysis and interpretation workflows for insights into the evolution and spread of the virus that causes COVID-19 disease. The new products are an expansion of QIAGEN’s broad offering of sample technologies, diagnostic tests and instruments, and research tools for use in the global effort to combat the COVID-19 pandemic.